MUSTANG BIO, INC. Capital Expenditures
MUSTANG BIO, INC. (MBIO) reported Capital Expenditures of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-03-28
- MUSTANG BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $0.00.
- MUSTANG BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was $30.00K, a 68.42% decline year-over-year.
- MUSTANG BIO, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- MUSTANG BIO, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- MUSTANG BIO, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $64.00K, a 97.64% decline from fiscal 2022.
- MUSTANG BIO, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $2.71M, a 31.91% decline from fiscal 2021.
- MUSTANG BIO, INC. payments to acquire property, plant, and equipment for fiscal 2021 was $3.99M, a 107.06% increase from fiscal 2020.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $0.00 10-K · filed 2025-03-28 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $30.00K derived: sum of 2 quarters · filed 2025-03-28 | $64.00K derived: sum of 3 quarters · filed 2025-03-28 | $64.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $34.00K derived: sum of 2 quarters · filed 2024-11-08 | $34.00K 10-Q · filed 2024-11-08 | $129.00K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $34.00K 10-Q · filed 2024-08-13 | $129.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.11M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-12 | $95.00K derived: sum of 2 quarters · filed 2024-03-11 | $1.07M derived: sum of 3 quarters · filed 2024-03-11 | $1.38M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $1.07M derived: sum of 2 quarters · filed 2024-03-11 | $1.38M derived: sum of 3 quarters · filed 2024-03-11 | $2.71M 10-K · filed 2024-03-11 |
| 2022-09-30 | $979.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.28M derived: sum of 2 quarters · filed 2023-11-14 | $2.62M 10-Q · filed 2023-11-14 | $4.00M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.64M 10-Q · filed 2023-08-14 | $3.02M derived: sum of 3 quarters · filed 2023-08-14 | $3.48M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.33M 10-Q · filed 2023-05-12 | $2.71M derived: sum of 2 quarters · filed 2023-05-12 | $3.17M derived: sum of 3 quarters · filed 2023-05-12 | $4.86M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.84M derived: sum of 2 quarters · filed 2023-03-30 | $3.53M derived: sum of 3 quarters · filed 2023-03-30 | $3.99M 10-K · filed 2023-03-30 |
| 2021-09-30 | $460.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.15M derived: sum of 2 quarters · filed 2022-11-14 | $2.61M 10-Q · filed 2022-11-14 | $3.31M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.15M 10-Q · filed 2022-08-11 | $2.85M derived: sum of 3 quarters · filed 2022-08-11 | $2.98M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $458.00K 10-Q · filed 2022-05-12 | $1.16M derived: sum of 2 quarters · filed 2022-05-12 | $1.29M derived: sum of 3 quarters · filed 2022-05-12 | $1.86M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $835.00K derived: sum of 2 quarters · filed 2022-03-23 | $1.40M derived: sum of 3 quarters · filed 2022-03-23 | $1.93M 10-K · filed 2022-03-23 |
| 2020-09-30 | $138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $702.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.23M 10-Q · filed 2021-11-12 | $2.12M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $564.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $1.09M 10-Q · filed 2021-08-16 | $1.98M derived: sum of 3 quarters · filed 2021-08-16 | $2.48M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $526.00K 10-Q · filed 2021-05-14 | $1.42M derived: sum of 2 quarters · filed 2021-05-14 | $1.92M derived: sum of 3 quarters · filed 2021-05-14 | $2.57M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $891.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $1.39M derived: sum of 2 quarters · filed 2021-03-24 | $2.05M derived: sum of 3 quarters · filed 2021-03-24 | $2.35M 10-K · filed 2021-03-24 |
| 2019-09-30 | $499.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $1.16M derived: sum of 2 quarters · filed 2020-11-06 | $1.45M 10-Q · filed 2020-11-06 | $1.76M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | $656.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $955.00K 10-Q · filed 2020-08-10 | $1.26M derived: sum of 3 quarters · filed 2020-08-10 | $2.41M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $299.00K 10-Q · filed 2020-05-11 | $603.00K derived: sum of 2 quarters · filed 2020-05-11 | $1.75M derived: sum of 3 quarters · filed 2020-05-11 | $6.49M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.45M derived: sum of 2 quarters · filed 2020-03-16 | $6.19M derived: sum of 3 quarters · filed 2020-03-16 | $6.87M 10-K · filed 2020-03-16 |
| 2018-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $5.89M derived: sum of 2 quarters · filed 2019-11-12 | $6.57M 10-Q · filed 2019-11-12 | $6.97M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $4.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $5.42M 10-Q · filed 2019-08-09 | $5.82M derived: sum of 3 quarters · filed 2019-08-09 | $5.84M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $676.00K 10-Q · filed 2019-05-10 | $1.08M derived: sum of 2 quarters · filed 2019-05-10 | $1.10M derived: sum of 3 quarters · filed 2019-05-10 | |
| 2017-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $424.00K derived: sum of 2 quarters · filed 2019-03-18 | $424.00K 10-K · filed 2019-03-18 | |
| 2017-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $22.00K 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |